Molecular Mechanism of Action and Potential Biomarkers of Growth Inhibition of Synergistic Combination of Afatinib and Dasatinib Against Gefitinib-Resistant Non-Small Cell Lung Cancer Cells

Oncotarget - United States
doi 10.18632/oncotarget.24814
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Synergistic Effect of Afatinib With Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib

PLoS ONE
Multidisciplinary
2013English

Molecular Mechanisms of Action and Potential Biomarkers of Growth Inhibition of Dasatinib (BMS-354825) on Hepatocellular Carcinoma Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2013English

Inhibition of SREBP Increases Gefitinib Sensitivity in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2016English

ERK Inhibition Represses Gefitinib Resistance in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2018English

Gefitinib Radiosensitizes Non-Small Cell Lung Cancer Cells Through Inhibition of Ataxia Telangiectasia Mutated

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2010English

Synergistic Combinations of Paclitaxel and Withaferin a Against Human Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2020English

Role of FBXW7 in the Quiescence of Gefitinib-Resistant Lung Cancer Stem Cells in EGFR-mutant Non-Small Cell Lung Cancer

Bosnian Journal of Basic Medical Sciences
Medicine
2019English

Enhancement of Epidermal Growth Factor Receptor-Degradation Pathway in Acquired Gefitinib-Resistant Human Non-Small Cell Lung Cancer Cell Lines

The Showa University Journal of Medical Sciences
2004English

Gefitinib for the Treatment of Non-Small-Cell Lung Cancer

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy